Advances on the combined immunotherapy for advanced unresectable hepatocellular carcinoma
10.3760/cma.j.cn113884-20200903-00474
- VernacularTitle:晚期不可切除肝癌免疫联合治疗相关进展
- Author:
Ze ZHANG
;
Shichun LU
- From:
Chinese Journal of Hepatobiliary Surgery
2021;27(3):222-226
- CountryChina
- Language:Chinese
-
Abstract:
Recently, the clinical trials of combined immunotherapy for advanced hepatocellular were completed successfully (Imbrave150, Keynote524), which have significantly increased the objective response rate and prolonged median overall survival time. The success of combined immunotherapy provides great potential and reality for subsequent surgical intervention of advanced hepatocellular carcinoma. Nowadays, the hot topics of combined immunotherapy include the choices of combined immunotherapy, the perioperative period determination, tumor immune microenvironment, and effective biomarkers of immunotherapy selection, and so on. This paper intends to summarize the above-related issues.
